J&J’s Ketamine-Derived Spravato Soars in Depression Treatment
From raves to rave reviews, Johnson & Johnson’s Spravato is transforming depression care with its ketamine-derived nasal spray. Originally used as a horse tranquilizer, ketamine gained notoriety in club scenes for its hallucinogenic effects — and now J&J has turned this controversial substance into an FDA-approved breakthrough treatment for depression. As Spravato’s adoption skyrockets, it’s not just improving patients’ lives — it’s reshaping mental health treatment.
- Analysts project $1B in 2024 sales, doubling from early 2023 — and J&J expects this to grow to $5B as Spravato becomes a key product in its portfolio.
- Unlike traditional antidepressants, which can take weeks to work, Spravato offers rapid relief — but patients must visit certified facilities, where they’re monitored for two hours post-administration.
A mind-bending breakthrough: Despite the controversy surrounding ketamine, many already self-prescribe it to manage depression, anxiety, and psychiatric disorders. Spravato users report feeling “pleasure … [and] a full range of emotions,” while others say it’s “set [them] forward leaps and bounds.” Aimed at those with conventional treatment-resistant depression, Spravato provides an alternative to traditional antidepressants — and J&J has managed to turn a party favorite into a profitable prescription.
